Editorial
|
|
|
|
|
EU and US regulators diverge on maraviroc
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Continue to use C1 esterase inhibitor
|
|
|
|
|
|
|
|
|
|
No evidence of comparative effectiveness
|
|
|
|
|
|
|
|
|
|
The SPC now contains more situations where patients are advised to consult a doctor
|
|
|
|
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Do not start treatment with fluindione, use warfarin instead
|
|
|
|
|
|
|
|
|
|
Patients should no longer be exposed to nicorandil
|
|
|
|
|
|
|
|
|
|
New Information on worrying cases reported in the US
|
|
|
|
Reviews
|
|
|
|
|
Uncertain balance between benefits and risks
|
|
|
|
|
|
Outlook
|
|
|
|
|
Useless guideline
|
|
|
|
|
|
|
|
|
|
|
|
HRA Pharma is not happy but fails to cite so-called errors and omissions in Prescrire assessment
|
|
|
|
|
|
|
|